跳至主要内容
临床试验/NCT02773355
NCT02773355已完成不适用

Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican Patients

Novo Nordisk A/S15 个研究点 分布在 1 个国家目标入组 27 人开始时间: 2016年5月16日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
27
试验地点
15
主要终点
Frequency of pancreatitis

研究概览

简要总结

This trial is conducted in North America. The aim is to investigate timely detection of pancreatitis cases as well as cases of suspicion of serious and non-serious adverse reactions possibly or probably related to Saxenda® in Mexican patients.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol)
  • The decision to initiate the treatment with commercially available Saxenda® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study
  • Obese patients (BMI equal to or above 30 kg/m^2) or overweight patients (BMI Equal to or above 27 kg/m^2) with at least one weight related comorbidity according to Saxenda® label text in Mexico
  • Age equal or above 18 years at the time of signing informed consent

排除标准

  • Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
  • Hypersensitivity to Saxenda® or to any of its excipients
  • Females of child-bearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (adequate contraceptive measures as required by local law or practice)
  • Diagnosis of type 1 diabetes

研究组 & 干预措施

Saxenda®

干预措施: liraglutide 3.0 mg (Drug)

结局指标

主要结局

Frequency of pancreatitis

时间窗: Year 0-3

次要结局

  • Adverse drug reactions (ADR)(Year 0-3)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (15)

Loading locations...

相似试验

Timely Detection of Treatment Emergent Serious and... | 临床试验